Cascadian Therapeutics Inc. (NASDAQ:CASC) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

Several other equities research analysts also recently issued reports on the stock. Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a research note on Monday. Jefferies Group restated a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $2.00 price objective on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $3.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 8.22% during trading on Tuesday, reaching $1.34. 1,143,916 shares of the company were exchanged. Cascadian Therapeutics has a 52-week low of $0.82 and a 52-week high of $3.75. The stock’s market capitalization is $181.32 million. The stock has a 50-day moving average of $1.33 and a 200 day moving average of $1.17.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.14. During the same period last year, the business posted ($0.11) EPS. On average, equities analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current fiscal year.

In other Cascadian Therapeutics news, insider Scott Dunseth Myers purchased 45,000 shares of the firm’s stock in a transaction on Wednesday, August 17th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $51,750.00. Following the completion of the purchase, the insider now directly owns 107,500 shares of the company’s stock, valued at $123,625. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 19.40% of the company’s stock.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with's FREE daily email newsletter.